Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems
GAITHERSBURG, Md., Aug. 25, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Novavax
Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials
NEW YORK, Aug. 24, 2021 -- Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled and ran
Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis
DUBLIN and SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmace
AZD7442 PROVENT Phase III Prophylaxis Trial Met Primary Endpoint in Preventing COVID-19
77% reduced risk of developing symptomatic COVID-19 First long-acting antibody combination to prevent COVID-19 20 August 2021 -- Positive high-level results from the PROVENT Phase III pre-exposure pro
NRx Pharmaceuticals Announces Positive Safety Report for Zyesami (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19
After Review of Approximately 140 patients in ACTIV-3 Critical Care Study, No New Safety Concerns Raised by Independent Data Safety Monitoring Board, Study to Continue Enrollment to Target More than 6
Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone Data support the use of toripalimab with chemotherapy as first-line therapy for pa
Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
SOUTH SAN FRANCISCO, August 18, 2021 -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engin
FDA Approves Trudhesa (dihydroergotamine mesylate) Nasal Spray for the Acute Treatment of Migraine
SEATTLE, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases
FDA Approves Invega Hafyera (paliperidone palmitate) for Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsych
Statement on Boosting with the Johnson & Johnson COVID-19 Vaccine
NEW BRUNSWICK, N.J., August 18, 2021 -- We are engaging with the U.S. FDA, CDC and other health authorities and will share new data shortly regarding boosting with the Johnson & Johnson COVID-19 v
Lilly's Lebrikizumab Significantly Improved Skin Clearance and Itch in People with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials
INDIANAPOLIS, Aug. 16, 2021 /PRNewswire/ -- Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (
Moderna Announces First Patient Dosed in Phase 1/2 Study of mRNA-3705 for Methylmalonic Acidemia
mRNA-3705 is Moderna’s second rare disease program to enter clinical studies mRNA-3705 granted Orphan Drug and Rare Pediatric Disease designation by the U.S. FDA MMA associated with significant mortal
News
- CanalLotus Biotech -
Int'l Clinical Service Expert
We are the leader
Because of our professionism
